# Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics

> **NCT03862079** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Graft-versus-host Disease Prevention

## Interventions

- **OTHER:** Best Practice
- **PROCEDURE:** Fecal Microbiota Transplantation
- **DRUG:** Nystatin
- **DRUG:** Piperacillin-Tazobactam

## Key facts

- **NCT ID:** NCT03862079
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-06-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per PI's request
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03862079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03862079, "Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03862079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*